New Alzheimer's Drugs Emerge From Rethinking the Disease's Cause

The Alzheimer’s Drug That Wasn’t

For decades, the story of Alzheimer’s disease was simple. A sticky protein called amyloid beta builds up in the brain, clumps into plaques, and kills neurons. If you clear the plaques, you stop the disease. That story convinced the pharmaceutical industry to spend billions on drugs that targeted amyloid. Almost all of them failed.

Then something strange happened. In 2021, the FDA approved aducanumab, a drug that clears amyloid plaques, despite evidence that it did not slow cognitive decline. In 2023, it approved lecanemab, another amyloid clearer, but this time with data showing it slowed memory loss by about 27 percent over 18 months (Zhang et al., 2024). The field had its first disease modifying drug. But the effect was modest. Patients and doctors wanted to know: Is that it?

The answer, according to a sweeping review published in Signal Transduction and Targeted Therapy, is that the amyloid hypothesis was never wrong. It was incomplete. The authors, led by Jifa Zhang of the Chinese Academy of Sciences, argue that Alzheimer’s is not one disease with one cause. It is a cascade of failures in the brain’s biology, and the drugs that will actually work are the ones that hit multiple targets at once (Zhang et al., 2024). The paper, which has already been cited 867 times, is a signal that the field is shifting. The question is where it is going.

What Actually Causes Alzheimer’s? The Field Has Nine Theories

The Zhang review catalogs nine distinct hypotheses for what drives Alzheimer’s. The list reads like a medical textbook of brain failures: cholinergic dysfunction, amyloid plaques, tau tangles, chronic inflammation, oxidative stress, metal ion imbalances, glutamate toxicity, disruptions in the gut brain axis, and faulty autophagy (Zhang et al., 2024). Each one has evidence behind it. Each one has drugs that failed when tested alone.

The authors are not arguing that all nine are equally important. They are arguing that the field has been asking the wrong question. Instead of “which one causes the disease,” the question should be “which combination of these failures is happening in this patient, and at what stage?”

This is a fundamental shift. For years, clinical trials enrolled patients based on a single diagnosis: Alzheimer’s. The Zhang review suggests that Alzheimer’s is more like a syndrome, where different biological pathways converge on the same final symptoms. A drug that blocks amyloid might help someone whose disease is driven by amyloid accumulation. It will do nothing for someone whose primary problem is tau tangles or inflammation.

Why the Amyloid Drugs Worked (Sort Of) and What They Missed

The approval of lecanemab was a landmark, but the Zhang review puts it in context. Lecanemab is a monoclonal antibody that binds to soluble amyloid beta protofibrils, the smaller, more toxic forms of the protein before they form plaques. It slows cognitive decline by about 27 percent over 18 months (Zhang et al., 2024). That is real. It is also not a cure.

The authors point out that lecanemab’s effect is likely limited because it only addresses one part of the cascade. Once amyloid starts accumulating, it triggers tau pathology, inflammation, and synaptic damage. By the time a patient has symptoms, the downstream damage is already underway. Clearing amyloid at that point is like fixing a leaky pipe after the house has flooded.

Aducanumab, the earlier drug, faced a different problem. It cleared plaques but did not consistently slow decline, leading to controversy over its approval. The Zhang review notes that aducanumab targets aggregated amyloid plaques, which may be less toxic than the soluble protofibrils that lecanemab hits (Zhang et al., 2024). In other words, the target matters as much as the mechanism.

The New Strategy: Drugs That Hit Multiple Targets at Once

The most interesting section of the review covers what the authors call “dual target inhibitors” and “multi target directed ligands.” These are drugs designed to interfere with two or more disease pathways simultaneously. The logic is straightforward: if Alzheimer’s is a cascade, you need to break it at multiple points.

One example the authors highlight is a class of compounds that inhibit both amyloid aggregation and tau hyperphosphorylation. Another targets both acetylcholinesterase (the enzyme that breaks down the neurotransmitter acetylcholine) and monoamine oxidase B (an enzyme linked to oxidative stress). These are not yet approved drugs, but they are in preclinical development (Zhang et al., 2024).

The review also discusses proteolysis targeting chimeras, or PROTACs. These are molecules that hijack the cell’s waste disposal system to tag toxic proteins like tau or amyloid for destruction. Unlike traditional inhibitors that block a protein’s function, PROTACs eliminate the protein entirely. The Zhang review calls this “a promising strategy” but notes that the technology is still early stage (Zhang et al., 2024).

What About Inflammation? The Immune System Connection

One of the most surprising findings in the review is the role of neuroinflammation. For years, inflammation was seen as a secondary effect of Alzheimer’s, a consequence of dying neurons. The Zhang review argues it may be a primary driver.

Microglia, the brain’s immune cells, become chronically activated in Alzheimer’s. They release inflammatory molecules that damage synapses and promote tau pathology. The review cites evidence that genetic variants in the TREM2 gene, which controls microglial function, increase Alzheimer’s risk as much as the well known APOE4 variant (Zhang et al., 2024). This suggests that calming the immune system could be a viable treatment strategy.

Several drugs targeting microglial activation are now in clinical trials. The Zhang review highlights a class of drugs called CSF1R inhibitors, which can reduce microglial activation in animal models. The question is whether reducing inflammation will help patients who already have significant amyloid and tau pathology, or whether it only works early in the disease.

The Gut Brain Connection: A Surprising New Target

The review includes a section on the microbiota gut brain axis, which is the most speculative but also the most intriguing piece. The idea is that the bacteria living in your gut produce metabolites that affect brain function. In Alzheimer’s patients, the gut microbiome is different from healthy controls. The Zhang review notes that certain bacterial metabolites, like short chain fatty acids, can reduce inflammation and improve cognitive function in animal models (Zhang et al., 2024).

No drugs targeting the gut microbiome have been approved for Alzheimer’s yet. But the review points to early stage clinical trials testing probiotics and fecal transplants. The authors are careful not to overstate the evidence. They write that “the precise mechanisms remain to be elucidated” (Zhang et al., 2024). But the fact that this pathway is now included in a major review signals that the field is taking it seriously.

What the Research Does Not Prove

The Zhang review is comprehensive, but it has limits. The authors are synthesizing existing studies, not reporting new data. Some of the mechanisms they discuss, like the gut brain axis, have strong animal evidence but weak human evidence. The dual target drugs they highlight are mostly in preclinical development. None have reached late stage clinical trials.

The review also does not resolve the biggest question in the field: Can Alzheimer’s be prevented? The authors note that lifestyle factors like diet, exercise, and cognitive engagement are associated with lower risk, but they do not provide a clear biological mechanism (Zhang et al., 2024). The evidence for prevention is epidemiological, not mechanistic.

Finally, the review does not address the cost and accessibility of new treatments. Lecanemab costs about $26,500 per year. Aducanumab was priced at $56,000 annually before its manufacturer discontinued it. If future drugs are combination therapies, the cost could be prohibitive for most patients.

What This Actually Means

• ▸Alzheimer’s is not a single disease with a single cause. It is a cascade of biological failures. Drugs that hit one target will have limited effects. The future is combination therapy, similar to how HIV is treated with multiple drugs at once.

• ▸The amyloid hypothesis was not wrong, but it was incomplete. Clearing amyloid helps, but only if you do it early, before downstream damage sets in. Diagnostic tests for amyloid and tau are becoming more accessible, which will allow earlier treatment.

• ▸Inflammation and immune dysfunction are emerging as primary targets, not secondary effects. Drugs that calm microglial activation could be effective, especially in patients with genetic risk factors like TREM2 variants.

• ▸The gut brain axis is a real biological pathway, but the evidence for treating Alzheimer’s through the microbiome is still weak. Do not buy probiotics marketed for brain health until clinical trials prove they work.

• ▸The most promising new drug technologies are PROTACs, which destroy toxic proteins rather than just blocking them, and dual target inhibitors, which hit multiple pathways at once. Both are in early development. Watch for phase 2 trial results in the next three to five years.